...
ocgn-img

Ocugen Inc, Common Stock

OCGN

NAQ

$0.7545

-$0.08

(-9.61%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$246.78M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
9.09M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
3.77
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.37 L
$2.1 H
$0.7545

About Ocugen Inc, Common Stock

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameOCGNSectorS&P500
1-Week Return-13.33%-2.06%-0.55%
1-Month Return-17.25%-1.92%2.72%
3-Month Return-32.68%-10.4%7.66%
6-Month Return-45.36%-4.6%10.15%
1-Year Return102.69%4.06%27.53%
3-Year Return-85.42%1.94%32.31%
5-Year Return96.35%36.48%89.2%
10-Year Return-99.89%97.46%194.59%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue42.62K42.62K22.92K2.49M6.04M[{"date":"2019-12-31","value":0.71,"profit":true},{"date":"2020-12-31","value":0.71,"profit":true},{"date":"2021-12-31","value":0.38,"profit":true},{"date":"2022-12-31","value":41.22,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue60.61K6.35K589.00K1.07M704.00K[{"date":"2019-12-31","value":5.65,"profit":true},{"date":"2020-12-31","value":0.59,"profit":true},{"date":"2021-12-31","value":54.89,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":65.61,"profit":true}]
Gross Profit(60.61K)36.27K(589.00K)(1.07M)5.33M[{"date":"2019-12-31","value":-1.14,"profit":false},{"date":"2020-12-31","value":0.68,"profit":true},{"date":"2021-12-31","value":-11.05,"profit":false},{"date":"2022-12-31","value":-20.12,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin(142.21%)85.09%(2569.81%)(43.13%)88.34%[{"date":"2019-12-31","value":-160.98,"profit":false},{"date":"2020-12-31","value":96.33,"profit":true},{"date":"2021-12-31","value":-2909.11,"profit":false},{"date":"2022-12-31","value":-48.82,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses14.16M14.33M58.03M84.87M71.57M[{"date":"2019-12-31","value":16.69,"profit":true},{"date":"2020-12-31","value":16.88,"profit":true},{"date":"2021-12-31","value":68.37,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":84.33,"profit":true}]
Operating Income(14.16M)(21.28M)(58.03M)(84.87M)(65.53M)[{"date":"2019-12-31","value":-1416261900,"profit":false},{"date":"2020-12-31","value":-2128471700,"profit":false},{"date":"2021-12-31","value":-5802800000,"profit":false},{"date":"2022-12-31","value":-8486800000,"profit":false},{"date":"2023-12-31","value":-6553100000,"profit":false}]
Total Non-Operating Income/Expense(7.85M)(1.26M)(468.00K)--[{"date":"2019-12-31","value":-784663300,"profit":false},{"date":"2020-12-31","value":-125685100,"profit":false},{"date":"2021-12-31","value":-46800000,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Pre-Tax Income(20.24M)(21.82M)(58.42M)(81.35M)(63.08M)[{"date":"2019-12-31","value":-2024263000,"profit":false},{"date":"2020-12-31","value":-2182195300,"profit":false},{"date":"2021-12-31","value":-5841700000,"profit":false},{"date":"2022-12-31","value":-8135100000,"profit":false},{"date":"2023-12-31","value":-6307800000,"profit":false}]
Income Taxes982.96K801.51K(52.00K)(4.00M)536.11K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":81.54,"profit":true},{"date":"2021-12-31","value":-5.29,"profit":false},{"date":"2022-12-31","value":-406.63,"profit":false},{"date":"2023-12-31","value":54.54,"profit":true}]
Income After Taxes(21.23M)(22.62M)(58.37M)--[{"date":"2019-12-31","value":-2122559300,"profit":false},{"date":"2020-12-31","value":-2262346800,"profit":false},{"date":"2021-12-31","value":-5836500000,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(20.24M)(21.82M)(58.37M)(81.35M)(63.08M)[{"date":"2019-12-31","value":-2024263000,"profit":false},{"date":"2020-12-31","value":-2182195300,"profit":false},{"date":"2021-12-31","value":-5836500000,"profit":false},{"date":"2022-12-31","value":-8135100000,"profit":false},{"date":"2023-12-31","value":-6307800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(21.23M)(22.62M)(58.37M)(77.83M)(63.08M)[{"date":"2019-12-31","value":-2122559300,"profit":false},{"date":"2020-12-31","value":-2262346800,"profit":false},{"date":"2021-12-31","value":-5836500000,"profit":false},{"date":"2022-12-31","value":-7783400000,"profit":false},{"date":"2023-12-31","value":-6307800000,"profit":false}]
EPS (Diluted)(4.34)(0.31)(0.29)(0.38)(0.24)[{"date":"2019-12-31","value":-434,"profit":false},{"date":"2020-12-31","value":-31,"profit":false},{"date":"2021-12-31","value":-29,"profit":false},{"date":"2022-12-31","value":-38,"profit":false},{"date":"2023-12-31","value":-24,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

OCGN
Cash Ratio 2.46
Current Ratio 2.58

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

OCGN
ROA (LTM) -47.98%
ROE (LTM) -103.29%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

OCGN
Debt Ratio Lower is generally better. Negative is bad. 0.34
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.66

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

OCGN
Trailing PE NM
Forward PE 15.22
P/S (TTM) 52.51
P/B 6.07
Price/FCF NM
EV/R 45.72
EV/Ebitda NM

FAQs

What is Ocugen Inc share price today?

Ocugen Inc (OCGN) share price today is $0.7545

Can Indians buy Ocugen Inc shares?

Yes, Indians can buy shares of Ocugen Inc (OCGN) on Vested. To buy Ocugen Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in OCGN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Ocugen Inc be purchased?

Yes, you can purchase fractional shares of Ocugen Inc (OCGN) via the Vested app. You can start investing in Ocugen Inc (OCGN) with a minimum investment of $1.

How to invest in Ocugen Inc shares from India?

You can invest in shares of Ocugen Inc (OCGN) via Vested in three simple steps:

  • Click on Sign Up or Invest in OCGN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Ocugen Inc shares
What is Ocugen Inc 52-week high and low stock price?

The 52-week high price of Ocugen Inc (OCGN) is $2.1. The 52-week low price of Ocugen Inc (OCGN) is $0.37.

What is Ocugen Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Ocugen Inc (OCGN) is

What is Ocugen Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Ocugen Inc (OCGN) is 6.07

What is Ocugen Inc dividend yield?

The dividend yield of Ocugen Inc (OCGN) is 0.00%

What is the Market Cap of Ocugen Inc?

The market capitalization of Ocugen Inc (OCGN) is $246.78M

What is Ocugen Inc’s stock symbol?

The stock symbol (or ticker) of Ocugen Inc is OCGN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top